SCHEMBL10347282

SCHEMBL10347282

CCCCCc1ccc(C)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.56
TDP1 Q9NUW8 2/20 0.56
RAB9A P51151 6/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
MAPT P10636 4/20 0.53
NPC1 O15118 4/20 0.53
STAT3 P40763 1/20 0.53
ATM Q13315 1/20 0.53
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
NFKB1 P19838 4/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 2/20 0.50
CYP3A4 P08684 2/20 0.50
HIF1A Q16665 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30665032 1.00 L3MBTL1 (0.56) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL17058993 0.98 RAB9A (0.55) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL487755 0.98 RAB9A (0.55) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL23011835 0.98 RAB9A (0.55) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL1971057 0.94 NFKB1 (0.56) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL10144466 0.87 SMN1; SMN2 (0.51) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL17053310 0.85 MAPT (0.54) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL487279 0.85 SMN1; SMN2 (0.50) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL17053288 0.83 LPL (0.45) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT
SCHEMBL10715805 0.83 RARB (0.58) L3MBTL1TDP1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308975-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2019-06-04 US disclosed
US-20180223330-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-08-09 US disclosed
US-9580425-B2 Pyrido[3,4-b] indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2017-02-28 US disclosed
EP-0365641-A1 PYRIDINE DERIVATIVES MERCK PATENT GmbH (DE) 1990-05-02 EP disclosed
WO-1989010356-A1 PYRIDINE DERIVATIVES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1989-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180223330-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 L3MBTL1 52/4885TDP1 3852/4885RAB9A 1793/4885
US-10308975-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates AADAC, PGLS, GLB1 L3MBTL1 241/4885TDP1 3491/4885RAB9A 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.